SAB Biotherapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$1.15 | -$1.15 | -$1.15 |
| Q2 2024 | 1 | -$1.11 | -$1.11 | -$1.11 |
| Q3 2024 | 2 | -$1.32 | -$1.04 | -$1.16 |
| Q1 2025 | 1 | -$0.89 | -$0.89 | -$0.89 |
| Q2 2025 | 1 | -$0.66 | -$0.66 | -$0.66 |
| Q3 2025 | 1 | -$0.67 | -$0.67 | -$0.67 |
| Q4 2025 | 1 | -$0.68 | -$0.68 | -$0.68 |
| Q1 2026 | 1 | -$0.82 | -$0.82 | -$0.82 |
| Q2 2026 | 1 | -$0.85 | -$0.85 | -$0.85 |
| Q3 2026 | 1 | -$0.88 | -$0.88 | -$0.88 |
| Q4 2026 | 1 | -$0.91 | -$0.91 | -$0.91 |
SAB Biotherapeutics, Inc. Earnings Date And Information
SAB Biotherapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-1.12 earnings per share for the quarter, missing analysts' consensus estimates of $-1.07 by $0.05. The company had revenue of 0 for the quarter and had revenue of 2.24 M for the year. SAB Biotherapeutics, Inc. has generated $-8 earnings per share over the last year ($-7.64 diluted earnings per share) and currently has a price-to-earnings ratio of -0.64. SAB Biotherapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 2nd, 2025 based on prior year's report dates.
SAB Biotherapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$1.07 | -$1.12 | -0.05 | $120,000 | $0 |
| 08/08/2024 | Q2 2024 | -$1.13 | -$0.79 | 0.34 | $263,137 | $263,137 |
| 05/20/2024 | Q1 2024 | -$0.98 | -$0.54 | 0.44 | $944,575 | |
| 03/28/2024 | Q4 2023 | -$3.86 | $305,011 | |||
| 11/13/2023 | Q3 2023 | -$1.00 | -$0.97 | 0.03 | $11,966 | $1.27 M |
| 08/21/2023 | Q2 2023 | -$1.60 | -$1.36 | 0.24 | $400,000 | $85,518 |
| 05/15/2023 | Q1 2023 | -$1.47 | $581,101 | |||
| 04/28/2023 | Q4 2022 | -$1.56 | $2.16 M | |||
| 11/14/2022 | Q3 2022 | -$1.47 | $6.85 M | $3.59 M | ||
| 08/09/2022 | Q2 2022 | -$1.30 | -$1.11 | 0.19 | $10.80 M | $6.35 M |
| 05/12/2022 | Q1 2022 | -$1.20 | $0.23 | 1.43 | $11.80 M | |
| 04/28/2023 | Q4 2021 | -$4.11 | $60.88 M | |||
| 11/22/2021 | Q3 2021 | -$0.09 | -$0.08 | 0.02 | $14.40 M | $0 |
| 08/09/2021 | Q2 2021 | -$0.68 | $0 | |||
| 05/21/2021 | Q1 2021 | $0.32 | $0 | |||
| 04/02/2021 | Q4 2020 | -$0.01 | $0 |
SAB Biotherapeutics, Inc. Earnings: Frequently Asked Questions
-
When is SAB Biotherapeutics, Inc.'s earnings date?
SAB Biotherapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 2nd, 2025 based off last year's report dates.
-
How can I listen to SAB Biotherapeutics, Inc.'s earnings conference call?
The conference call for SAB Biotherapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read SAB Biotherapeutics, Inc.'s conference call transcript?
The conference call transcript for SAB Biotherapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does SAB Biotherapeutics, Inc. generate each year?
SAB Biotherapeutics, Inc. (:SABS) has a recorded annual revenue of $2.24 M.
-
How much profit does SAB Biotherapeutics, Inc. generate each year?
SAB Biotherapeutics, Inc. (:SABS) has a recorded net income of $2.24 M. SAB Biotherapeutics, Inc. has generated $-7.64 earnings per share over the last four quarters.
-
What is SAB Biotherapeutics, Inc.'s price-to-earnings ratio?
SAB Biotherapeutics, Inc. (:SABS) has a price-to-earnings ratio of -0.64 and price/earnings-to-growth ratio is 0.26.
